Infectious Disease and Microbiome Program

Over the last seven years, the ӳý of MIT and Harvard has helped systematically uncover, catalog, and analyze the microbial inhabitants of the human microbiome. Research is now focused on using “multi-omics” techniques, including whole genome sequencing, as well as proteomic, metabolomic, and transcriptomic analyses, to better understand how the microbiota is acting on and interacting with its human hosts in health, and during disease progression.

In one of the largest longitudinal studies of the microbiome to date, researchers from the ,  (MGH), and the  Study Group have identified a connection between changes in gut microbiota and the onset of type 1 diabetes (T1D). The study, which followed infants who were genetically predisposed to the condition, found that onset for those who developed the disease was preceded by a drop in microbial diversity – including a disproportional decrease in the number of species known to promote health in the gut. These findings, , could help pave the way for microbial-based diagnostic and therapeutic options for those with T1D.

In recent years, there has been a growing awareness that our bodies are not entirely our own: each of us contains a delicate ecosystem comprised not only of human cells, but also trillions of microorganisms – bacteria, viruses, and other assorted “bugs” – that reside in our bodies. Within the human gut, as in any ecosystem, this balance can easily be disrupted, with devastating consequences.